# Lunit

Source: https://onco.cc/companies/lunit/  
OnCo record `lunit` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Korean AI company spanning mammography reading (INSIGHT MMG), breast-density risk (Volpara), and AI pathology for immunotherapy biomarkers.

## Summary

21 studies at ECR 2026 covering INSIGHT MMG, Scorecard (ex-Volpara density), and INSIGHT CXR; a large Dutch randomised trial using Scorecard showed supplemental MRI in dense breasts reduced advanced cancer incidence. Lunit SCOPE pathology AI partnered with Labcorp and CellCarta (2025-26) for companion diagnostics. In September 2025 Lunit acquired Prognosia, a 2024 spin-out from Washington University School of Medicine that developed a breast cancer risk prediction algorithm; no deal value was disclosed.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- HQ: Seoul
- Type: ai-software
- Website: https://www.lunit.io
- Ticker: 328130.KQ

## Notes

- Freshened 29 October 2026: the Prognosia acquisition is listed in Lunit's own newsroom, which links to The Imaging Wire report used here; Lunit's own release on it was not read. No acquisition of Lunit, merger or delisting was found.

## Sources

- ECR 2026: https://www.prnewswire.com/news-releases/lunit-to-be-featured-in-21-ai-imaging-studies-on-breast-cancer-and-lung-disease-at-ecr-2026-302703651.html
- Lunit acquires Prognosia (The Imaging Wire, September 2025): https://theimagingwire.com/2025/09/03/lunit-is-ramping-up-its-position-in-breast-cancer-risk/

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- fronts: [AI & Computation](https://onco.cc/fronts/ai-computation/), [Early Detection & Screening](https://onco.cc/fronts/early-detection/), [Imaging](https://onco.cc/fronts/imaging/)
- technologies: [AI in radiology](https://onco.cc/technologies/radiology-ai-screening/), [Digital pathology & AI](https://onco.cc/technologies/digital-pathology-ai/), [Mammography & tomosynthesis](https://onco.cc/technologies/mammography/)
- companies: [Volpara Health](https://onco.cc/companies/volpara-health/)
- bottlenecks: [AI that is built but not validated or deployed](https://onco.cc/bottlenecks/b-ai-validation/), [Not enough oncologists, nurses, pathologists, physicists](https://onco.cc/bottlenecks/b-workforce/)
- ideas: [AI clears the normal lung screening scans so radiologists read only the suspicious ones](https://onco.cc/ideas/idea-prev-ldct-ai-negative-triage/), [AI-assisted central imaging reads to cut endpoint cost and variability](https://onco.cc/ideas/idea-tr1-ai-central-imaging-reads/), [AI-first reading for high-volume common cancer diagnoses, pathologist for the exceptions](https://onco.cc/ideas/idea-acc-ai-first-pathology-common-cases/), [No clinical claims for imaging-derived biomarkers without phantom and standards compliance](https://onco.cc/ideas/idea-tr2-radiomics-ibsi-mandate/), [Roll out AI-supported mammography nationally as a stepped-wedge trial](https://onco.cc/ideas/idea-prev-mammography-ai-stepped-wedge/), [Set each woman's mammogram interval from her last mammogram, using AI risk](https://onco.cc/ideas/idea-prev-ai-mammogram-risk-intervals/), [Turn the map of immune cells inside a tumour into a standardised test](https://onco.cc/ideas/idea-bio2-spatial-signature-cdx/)
- drugs: [Lunit INSIGHT MMG](https://onco.cc/drugs/lunit-insight-mmg/)
- trials: [ScreenTrustCAD](https://onco.cc/trials/screentrustcad/)
- key papers: [Artificial intelligence for breast cancer detection in screening mammography in Sweden: a prospective, population-based, paired-reader, non-inferiority study (ScreenTrustCAD)](https://onco.cc/key-papers/paper-screentrustcad-dembrower-lancet-digit-health-2023/)

---
JSON: https://onco.cc/api/v1/entities/lunit.json